Dissecting major signaling pathways in prostate cancer development and progression: Mechanisms and novel therapeutic targets
详细信息    查看全文
文摘
Androgen deprivation therapy (ADT) is treatment of choice for recurrent PCa. Patients eventually develop CRPC- a more advanced and resistant PCa phenotype. Host of molecular alterations are involved in acquiring resistance to ADT and CRPC. Array of drugs are precisely designed to target aberrant signaling pathways. Review summarizes key aberrant pathways in PCa and therapeutics influencing them.

© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号

地址:北京市海淀区学院路29号 邮编:100083

电话:办公室:(+86 10)66554848;文献借阅、咨询服务、科技查新:66554700